SCHEMBL27374381

SCHEMBL27374381

CC(C)(C)OC(=O)c1c(CBr)cccc1C1CCC(F)(F)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ IL1B P01584 4/20 0.33
▸ P2RX7 Q99572 3/20 0.33
▸ SLC6A2 P23975 2/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ IDH2 P48735 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ GPR119 Q8TDV5 2/20 0.32
▸ SCN9A Q15858 2/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KCNH2 Q12809 2/20 0.31
▸ HTR1A P08908 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ CHRM2 P08172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27362604 0.89 SLC6A2 (0.33) MEN1KMT2AATMIL1BP2RX7
SCHEMBL27375857 0.88 MEN1 (0.36) MEN1KMT2AATMIL1BP2RX7
SCHEMBL27371832 0.86 SCN9A (0.34) MEN1KMT2AATMSLC6A2SLC6A4
SCHEMBL27375885 0.85 CA12 (0.37) MEN1KMT2AATMIL1BP2RX7
SCHEMBL27378973 0.85 MEN1 (0.38) MEN1KMT2AATMIL1BP2RX7
SCHEMBL30755212 0.85 CA12 (0.37) MEN1KMT2AATMIL1BP2RX7
SCHEMBL27377777 0.84 GPR119 (0.36) IL1BP2RX7IDH1IDH2GPR119
SCHEMBL30755349 0.84 GPR119 (0.36) IL1BP2RX7IDH1IDH2GPR119
SCHEMBL30755381 0.83 P2RX7 (0.35) IL1BP2RX7
SCHEMBL27379422 0.83 P2RX7 (0.35) IL1BP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
EP-4562016-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
WO-2024026483-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 MEN1 3868/4885KMT2A 607/4885ATM 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback